Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Alexion Pharmaceuticals Is Surging Today

By Brian Feroldi – Apr 26, 2018 at 4:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Traders cheer an upbeat earnings report and positive clinical news. Here's what investors need to know.

What happened

In response to the company reporting expectation-topping first-quarter results and sharing upbeat pipeline news, shares of Alexion Pharmaceuticals (ALXN) jumped 12% as of 3:15 p.m. EDT on Thursday.

So what

Here's a review of the key takeaways from the first quarter:

  • Revenue jumped 7% to $931 million. That was ahead of the $923 million in revenue that Wall Street had predicted.
  • Adjusted earnings were $1.68 per share. By contrast, analysts were only expecting $1.50.
  • The company shared top-line results from a phase 3 study of ALXN1210, which is a long-acting version of Alexion's blockbuster drug Soliris. The study showed that patients with paroxysmal nocturnal hemoglobinuria (PNH) can be effectively and safely switched from Soliris to ALXN1210. That's great news, because patients will only have to receive treatment every eight weeks when using ALXN1210 instead of every two weeks on Soliris.

The upbeat first-quarter results caused management to raise its guidance for the full year:

Metric Old Guidance Updated Guidance
2018 Revenue $3.850 billion to $3.950 billion $3.925 billion to $3.985 billion
Non-GAAP Earnings $6.60 to $6.80 $6.75 to $6.90

Data source: Alexion Pharmaceuticals. GAAP = generally accepted accounting principles.

Given the strong quarterly results, exciting clinical news, and bullish guidance, it isn't hard to figure out why Alexion is soaring today.

Man with money in his hands

Image source: Getty Images.

Now what

It's been a couple of tumultuous years for Alexion's shareholders, so it's nice to see that the company might finally be back on its feet. The upbeat news on ALXN1210 is especially exciting since, if approved, the drug could help the company get out ahead of the encroaching competition.

So is Alexion finally a buy? I'm not convinced that the answer to that question is "yes" just yet. However, if the company can produce a few more quarters like this, I'd be happy to change my tune.

Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alexion Pharmaceuticals, Inc. Stock Quote
Alexion Pharmaceuticals, Inc.
ALXN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.